CRISPR Therapeutics (CRSP) is higher today as traders key in on management’s recent “second phase” messaging following the launch of Casgevy, emphasizing a broader pipeline and a denser schedule of expected clinical and preclinical updates over the next 6–12 months. Commentary from the Needham Virtual Healthcare Conference has refocused attention on multiple 2026 milestones across cardiovascular, autoimmune/oncology (zugo-cel), and other programs, encouraging incremental risk-on positioning in the name. (defenseworld.net)

CRSP also sits with high reported short interest, which can mechanically increase volatility on up days when buyers press and shorts reduce exposure. As of March 31, 2026, short interest was reported at about 22.62 million shares, representing roughly 24.62% of the public float, a setup that can accelerate price action on bullish narrative shifts even without a same-day headline. (marketbeat.com)

Near-term focus is on the company’s 2026 milestone timeline, including additional program updates later in 2026 and the cadence of readouts management has flagged in the second half of the year. Investors are also watching for continued evidence that Casgevy access and reimbursement progress translate into a steadier commercial ramp, as that remains the bridge between pipeline optionality and a more durable financial inflection. (ir.crisprtx.com)